Background. According to death certificates, approximately 1800 persons die from hepatitis B annually in the United States; however, this figure may underestimate true mortality from chronic hepatitis B (CHB).
Chronic hepatitis B (CHB), an indolent viral infection, progresses over decades to cirrhosis, liver failure, hepatocellular carcinoma, and premature death [1] [2] [3] in some patients. In the United States, about 1800 death certificates annually list hepatitis B virus (HBV) as an underlying or contributing cause of death [4] . However, accurately quantifying mortality related to hepatitis is difficult because of the prolonged period between infection and death and because death is not always linked to the underlying infection [5] . Manos et al. [6] found that only 48% of the deaths that were identified as HBV-associated in the medical records of patients with chronic liver disease were also captured as HBV-associated on their death certificates.
Underestimating the true prognosis of CHB infections may have real consequences for patients. Adults known to have high prevalences of CHB infections-including foreign-born AsianPacific Islanders [7] , racial and ethnic minorities [8] , and adults diagnosed with sexually transmitted infections [9] -are often not screened for HBV as recommended. Many high-risk adults are also not vaccinated against hepatitis B [9] [10] [11] . Even patients diagnosed with CHB receive less than the recommended monitoring to document changes in the disease activity or any development of hepatocellular carcinoma [12] [13] [14] , which would allow them to receive timely and effective treatment.
The National Academies of Sciences, Engineering, and Medicine recently determined that hepatitis B elimination is feasible through vaccinations at birth, to infants, and to highrisk adults, and through screening and treatment of HBVinfected adults [15] ; they recommended enhanced estimates of morbidity and mortality to guide elimination efforts [16] . Therefore, using data from the Chronic Hepatitis Cohort Study (CHeCS), we sought to (1) describe baseline demographic and clinical characteristics of CHB decedents and survivors, and (2) compare mean ages at death and all-cause and cause-specific mortality rates between CHB decedents and other U.S. decedents through the Multiple Cause of Death (MCOD) file.
METHODS

Study Population and Follow-up
Based on a study of hepatitis C mortality [17] , we hypothesized that reported deaths underrepresent the true mortality from hepatitis B. Methods for CHeCS data collection and inclusion criteria for patients with chronic hepatitis B (CHB) have been described [18] [19] [20] . Briefly, the cohort is based on electronic health records (EHR) for patients aged ≥18 years who received outpatient, inpatient, emergency department, or laboratory services on or after 1 January 2006 at 1 of 4 large health systems: Geisinger Health System in Danville, Pennsylvania, serving approximately 2.6 million Pennsylvania residents in 44 counties; Henry Ford Health System in Detroit, Michigan, serving over 1 million southeast Michigan residents; Kaiser Permanente-Northwest in Portland, Oregon, serving approximately 500 000 members; and Kaiser PermanenteHonolulu in Honolulu, Hawaii, serving about 220 000 patients, or approximately one-sixth of the Hawaiian population. Patients were classified as having CHB primarily by laboratory results and secondarily based on International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) diagnosis codes [18] [19] [20] [21] . Electronically-available data were supplemented with reviews of EHR text fields to collect additional information on demographics, hepatitis treatments, non-electronic laboratory results from other medical facilities, and liver biopsy results. Following standard procedures, trained personnel performed medical record abstraction for all patients in the original 2006-2008 cohort. Due to capacity and funding constraints, patients meeting electronic cohort criteria after 2008 were selected by simple random sampling for chart abstraction as funding allowed [19] ; a final total of 69% of all patients meeting HBV cohort eligibility criteria had data abstraction. After data abstractors confirmed CHB infection from medical records or an electronically-available test that detects viral hepatitis nucleic acid, all available retrospective data back to the first health system visit was included for enrolled patients.
Each study site compares cohort patient records with the National Death Index, Social Security Death Index, or electronic state death registries annually [17] for those patients known to have died or for those not seen in the health system for 2 years. Deaths are also ascertained from hospitals and clinics reporting through the EHR. EHR-reported deaths without a matching death certificate do not have MCOD data.
Follow-up was defined to begin on 1 January 2006, regardless of the date of first visit, and age was calculated from date of birth as of that date. The study population included patients receiving their first clinical services through 31 December 2013. Follow-up was truncated on 31 December 2014 or the date of death, whichever came first.
Demographic and Clinical Data
Baseline demographic data and mean follow-up time in years were analyzed for CHB decedents and survivors based on data extracted from the EHR. Geocoded addresses obtained at the time of entry into the cohort were matched to U.S. census data in order to estimate each household's income. Insurance status was defined as of the most recent visit. Positive hepatitis B e antigen (HBeAg) was defined as any positive laboratory value reported during follow-up. HBV deoxyribonucleic acid levels were defined as the first available level. Baseline FIB-4 (fibrosis) score was calculated as the average of [Age(years)*aspartate transam- . Hepatocellular carcinoma was ascertained through validated tumor registry data. We defined "ever treated for CHB" as any prescription for medication licensed for treatment of hepatitis B.
Comparisons With Multiple Cause of Death Data
We calculated all-cause and cause-specific death rates for CHeCS CHB patients by dividing the number of deaths from 2006 through 2014 among CHB patients by the total person-years among CHeCS CHB population seen between 2006 and 2013. We used groupings of International Classification of Diseases, Tenth Revision (ICD-10) codes to classify causes of death as hepatitis B (B16, B16.x, B17.0, and B18.0, B18.1); hepatitis C (B 17.1, B18.2); liver-related, non-alcohol (K71-K77); liver-related, alcohol (K70); liver cancer (C22, D37.6); other hepatitis-related (B15, B15.x, B17.2, B17.8, B17.9, B18.8, B18.9, B 19, B94.2); HIV (B20-B24); cancer, except liver cancer (C00-C97 [except C22] and D37-48 [except D37.6]); circulatory (I00-I99); respiratory (J00-J99); diabetes (E10-E14); genitourinary (N00-N99); injuries and trauma (S00-S99, T00-T98, V01-V99, W00-W99, X00-X99 and Y00-Y36); mental and behavioral disorders (F00-F99) ; digestive, extra-hepatic (K00-K67 and K80-K93); and other (ICD-10 codes not specifically listed in any of our other classifications) [17] . Deaths were classified as belonging to a group if the underlying cause of death or MCOD fell into that category; decedents could be classified in more than one category if they had more than one cause of death. All-cause and cause-specific death rates were calculated per 100 000 person-years among CHeCS CHB patients and adjusted to the age distribution of the 2010 U.S. census population. For comparison, we calculated all-cause and cause-specific death rates from the U.S. MCOD database using data from 2006-2014 and the same ICD-10 grouping and age criteria, per 100 000 US population age-adjusted to the U.S. 2010 Census.
We calculated mean age at death for CHeCS CHB decedents for all-cause and cause-specific deaths, and compared that number with the mean age at death for adults aged ≥18 years from the 2006-2014 MCOD file.
Death Certificate Reporting of Hepatitis B Virus Infection
For all-cause and cause-specific deaths of CHeCS CHB decedents, we calculated the proportion of deaths for which hepatitis B was listed as underlying cause or contributing cause of death, defined as ICD-10 codes B16, B17.0, B18.0, and B18.1.
We also compared coding on the EHR for cirrhosis, hepatocellular carcinoma, or liver transplantation versus coding on the death certificate for hepatitis B or any liver disease. Liver disease included ICD-10 codes for liver-related conditions (K70-77), hepatocellular carcinoma (C22, D37.6), and hepatitis (B15-B19).
Statistical Analysis
SAS version 9.4 (SAS Institute Inc., Cary, NC) was used to prepare data for analysis, calculate unadjusted descriptive statistics on baseline characteristics and age-adjusted mortality rates, and compare the mortality rates and mean ages at death between CHeCS and MCOD data. All-cause and cause-specific mortality rates were calculated per 100 000 person-years within the follow-up period. We used the Pearson Chi-square test for testing differences in percentages and t-tests for testing differences in mean ages and follow-up years. All tests were 2 sided. A P value < .05 was considered statistically significant.
RESULTS
A total of 4389 patients with CHB, seen at 1 of 4 participating medical centers during 2006 through 2013, were followed for a mean of 5.38 years through 31 December 2014. During that timeframe, 492 (11%) CHB patients died, after a mean follow-up of 3.00 years.
Demographic and Clinical Descriptive Data
Demographic and clinical variables for CHeCS CHB decedents and survivors are shown in Table 1 . Compared to survivors, decedents were older and twice as likely to be White or African-American. Survivors were more than twice as likely as decedents to be Asian (48.8% vs. 18.4%). Decedents were significantly more likely than survivors to have evidence of cirrhosis (59.8% vs. 12.0%, P < .001). Decedents were also more likely to have evidence of diabetes, a history of alcohol abuse, a hepatitis C or HIV coinfection, hepatocellular carcinoma, a liver transplantation, or a history of treatment for CHB (all P < .001, compared with survivors).
Mortality
Death certificates with MCOD data were available for 409 (83%) CHeCS CHB decedents. Cause-specific and all-cause age-adjusted mortality rates during 2006-2014 for CHeCS patients with CHB were compared with the general U.S. population through the MCOD file, and are shown as sorted by relative risk in Sorted in ascending order, mean ages at death were compared for CHeCS CHB patients and the U.S. general population (MCOD) in Table 3 . On average, patients with CHB died significantly younger from all causes than persons in the general population (59.8 vs. 73.9 years, P < .0001). CHeCS CHB patients died, on average, before age 60 from HIV, alcohol-related liver disease, hepatitis C, other hepatitis causes, and non-alcohol-related liver disease. These differences were only significant for non-alcohol-related liver disease (59.3 years for CHeCS CHB patients versus 63 years for MCOD data, P = .0013) and other hepatitis causes (56.4 years for CHeCS CHB patients versus 62.6 years for MCOD data, P = .0158). For CHeCS CHB patients, the mean age at death for most non-hepatitis causes, such as respiratory illness, circulatory illness, and diabetes, was 60.5 to 63.5 years: for each cause, this mean was 10 to 16 years younger for those same causes in the U.S. population as a whole.
Death Certificate Reporting
Overall, 78 (19%) of 409 CHeCS CHB patients with matching death certificates had hepatitis B reported on the death certificate. In addition, only 40% of CHB patients with non-alcoholic liver disease, 13% of CHB patients with alcoholic liver disease, 29% of CHB patients with liver cancer, 50% of CHB patients with hepatitis C, and 33% of patients with another form of hepatitis had hepatitis B reported on the death certificate. For patients with any liver disease, including hepatitis B, reported on the death certificate, 40% had hepatitis B documented among the causes of death (Table 4) . We also evaluated the proportion of CHeCS CHB decedents who had liver disease coded in the EHR (Table 5) . Of 249 CHeCS CHB decedents with cirrhosis by any criteria, 69 (27.7%) had hepatitis B and 159 (66.3%) had any liver disease reported on the death certificate. Hepatitis B was also less likely than any liver disease to be reported on the death certificate for patients with liver cancer (29.3% vs. 100%) or liver transplantation (12.0% vs. 80.8%).
DISCUSSION
Compared to the general population, CHeCS CHB patients died at higher rates from all causes and from liver-related causes, including liver cancer. They also died, on average, 14 years younger than decedents in the general population. Almost half (48%) of CHB decedents died at an average age of <60 years, with liver disease listed as an underlying or contributing cause of death on the death certificate. Despite this, only 40% of CHB decedents dying with liver disease had hepatitis B reported as an underlying or contributing cause on the death certificate. Although the relative contribution of HBV to any individual death cannot always be determined with CHeCS data, our study suggests a meaningful effect of CHB on mortality for people living with this chronic infection. Because risk-based screening is incompletely implemented in medical practices [7] [8] [9] , only 26% of persons with CHB were aware of their infection in the 2011-2014 National Health and Nutrition Examination Survey [26] . In fact, 41% of CHeCS CHB patients reported that they were first diagnosed with hepatitis B because of clinical symptoms [27] . Among patients in ongoing medical care with clinical indications for testing (2 or more abnormal ALT levels), less than half were subsequently tested for hepatitis B and an estimated one-fifth of CHB patients in care went undiagnosed with hepatitis B infection [28] . Patients diagnosed with CHB are unlikely to be followed optimally to detect the development of cirrhosis and hepatocellular carcinoma [12] [13] [14] . Finally, our data demonstrate that even patients with documented complications of CHB, including cirrhosis, liver transplantation, or liver cancer, were unlikely to have the diagnosis of hepatitis B recorded on their death certificate. To summarize, many patients with CHB are unlikely to be diagnosed [7] [8] [9] [26] [27] [28] ; their fibrosis or other hepatic complications may go undetected [12] [13] [14] ; and their chronic infection with hepatitis B is unlikely to be recorded at the time of death. Others have confirmed that hepatitis B is associated with premature death and with elevated rates of death from all causes and from liver-related causes, including hepatocellular carcinoma [29] [30] [31] . Similar to our findings, diabetes [32, 33] and alcohol abuse [33, 34] are associated with an increased risk of death in persons with CHB. HIV coinfection also confers an increased risk of death [30, 35] , especially in cirrhotic patients [35] . Although some have postulated a protective effect of hepatitis C viral infection on mortality from hepatitis B [36] , other data demonstrates worse outcomes from hepatitis B and C coinfection compared to mono-infection [37, 38] . We were unable to evaluate the contribution of tobacco use in our study; however, smoking has been identified as a risk factor for hepatocellular carcinoma among persons with CHB [39] . Strengths of the study include similarities in age at death between the CHeCS CHB population and hepatitis B decedents in the MCOD data, and similar demographic [6, 26, 29] and prognostic [29, 30, 32, 35, 38] factors as those identified in other U.S. studies, suggesting that the CHeCS CHB decedents are similar to CHB decedents in the U.S. general population.
Limitations to our analysis include missing death certificates for 83 (17%) CHB decedents. BMI was missing for 13% of the CHeCS population and 34% of decedents. Smoking data was available for only 10% of the study population and was omitted from this analysis. In addition, laboratory test results were unavailable for many patients [12] , including hepatitis e antigen (29.9%), HBV deoxyribonucleic acid level (35.7%), and FIB-4 (22.5%) results. Also, hepatitis B screening tests may not be ordered for high-risk persons, leading to underreporting of chronic hepatitis B [28] . EHR coding underestimates alcohol abuse [25] and may underestimate other clinical parameters. Finally, the CHeCS cohort represents people who received documented medical care for hepatitis B on at least 2 occasions that were 6 or more months apart, and is thus lacking representation from incarcerated persons, uninsured persons, and persons with limited or sporadic access to health care [18] .
In conclusion, we observed increased prevalences of cirrhosis and other liver-related complications among CHB decedents compared to survivors, and increased risks of death from all causes and from all liver-related causes among CHB patients compared to the U.S. population. CHB patients also died, of all causes, on average, 14 years younger than persons in the general population. Almost half of these patients died at an average age of <60, with liver disease listed as an underlying or contributing cause. Despite this, only 40% of CHB decedents dying of liver disease had hepatitis B reported on their death certificates, implying that national vital statistics data substantially underestimate the mortality burden of HBV. These findings strongly support hepatitis B elimination as a national public health goal [15, 16] . Clinicians can contribute to elimination of hepatitis B by (1) vaccinating all unvaccinated high-risk adults for HBV; (2) appropriately screening all high-risk persons for HBV; and (3) assuring that persons with HBV receive posttest counseling and clinical care [40] . 
Notes
